Real-World Data Shows Immunotherapy Benefits in HCC, But Liver Health Matters

Immunotherapy-based treatments are making a real difference for people with hepatocellular carcinoma (HCC), the most common type of liver cancer. A recent study published ‍in JCO Global Oncology sheds light on how these treatments perform in a real-world setting, confirming⁤ their effectiveness and safety while also highlighting the critical role of liver health in predicting outcomes.

Immunotherapy in HCC: A Real-World Perspective

This retrospective study, ⁣led by Dr. Leonardo Gomes da Fonseca⁤ from Oncology D’Or and institute of Research and teaching in Sao Paulo, Brazil,⁢ analyzed data from 148 patients with advanced HCC treated with immunotherapy at 13 centers in Brazil. The goal was to understand how these treatments perform outside the controlled environment of ⁢clinical trials. The study included patients treated with various immunotherapy regimens, with a data cutoff of October 24, 2024.

Patient monitoring included regular radiologic assessments using Response Evaluation Criteria in‍ Solid Tumors v1.1 (RECIST) and tracking of adverse events using the National ‍Cancer Institute Common Terminology Criteria for⁢ Adverse Events v5.0.

Key findings: survival, Safety, and Predictors

The study revealed several important insights:

Overall survival: The median overall survival for the entire group was 14.7 months (95%⁤ CI, 11.6-24.5), with 12- and 24-month survival‍ rates of 57.0% (95% CI, 47.7%-65.3%) and 41.4% (95% CI, 30.1%-51.5%), respectively. This demonstrates the potential for long-term survival benefits with ⁢immunotherapy in HCC.
Impact of Liver Function: Patients with better liver function, classified as Child-Pugh A and an Eastern cooperative Oncology Group (ECOG) ⁢performance status of 0-1 (n = 116), experienced a substantially ⁣longer median overall survival of 20.6 months (95% CI, 12.4-25.8). This underscores the importance of baseline liver health in predicting treatment success.
Adverse Events: Immune-related adverse events (irAEs) occurred in 19.6% of ‍patients, primarily involving thyroid disorders and ⁣skin issues. bevacizumab-related events, such as variceal and other ‍bleeding events, were also observed. The safety profile was generally consistent ⁢with what’s been seen in clinical trials.
Predictors of Worse Survival: The study identified three⁤ self-reliant predictors of worse survival:
Albumin-bilirubin grade 2 to 3 (HR, 2.87; 95% CI, 1.31-6.31; P = .008)
Metabolic dysfunction-associated steatotic liver disease (MASLD) ⁤(HR,⁢ 3.87; 95% CI, 1.37-0.94; P = .011)
Esophageal Varices (HR, 1.67; 95% CI, 1.39-1.90; P* = .005)

These findings emphasize the need to carefully assess liver function and pre-existing conditions before initiating immunotherapy in HCC patients.

The Importance of Liver Health in HCC ‍immunotherapy

These real-world results reinforce the idea that while immunotherapy offers hope⁤ for HCC patients, the condition of their liver plays a ⁣crucial role in determining how well they respond to treatment. Patients with more advanced liver disease or pre-existing⁤ conditions like MASLD and esophageal varices may not experience the⁣ same benefits as⁤ those with healthier livers.

Tailoring Treatment Strategies for HCC

“In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline ⁢variceal status,” the authors wrote. “These⁤ findings highlight the relevance⁤ of baseline liver disease characteristics ‍in guiding immunotherapy in HCC and underscore the need for tailored management strategies.”

This means ⁢that doctors need to consider each‍ patient’s individual liver health when deciding if immunotherapy is the right choice and⁤ how to best manage their treatment. For example, patients with esophageal varices may need to be carefully monitored for bleeding risks, while those with MASLD may